View in EDS

Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.

Saved in:
Bibliographic Details
Title: Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.
Authors: Lauer UM; Department of Internal Medicine VIII, Medical Oncology & Pneumology, University Hospital Tübingen, Tübingen, Germany; German Cancer Research Center (DKFZ), Member of the German Cancer Consortium (DKTK), Tübingen, Germany. Electronic address: ulrich.lauer@uni-tuebingen.de., Awada A; Oncology Medicine Department, Jules Bordet Institute, Brussels, Belgium., Postel-Vinay S; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; INSERM Unit U981, Gustave Roussy, Villejuif, France; University College of London Cancer Institute, London, UK., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA., Thieblemont C; Université Paris Cité & Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Hémato-oncologie, Paris, France., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, USA., Paik PK; Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Shepard DR; Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, USA., Docampo LI; Lung and Head and Neck Cancer Unit, Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Galot R; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), Brussels, Belgium., Rottey S; Drug Research Unit Ghent, Ghent University Hospital, Ghent, Belgium., Sadrolhefazi B; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, USA., Marzin K; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany., Musa H; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Schöffski P; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
Source: ESMO open [ESMO Open] 2025 May; Vol. 10 (5), pp. 104499. Date of Electronic Publication: 2025 Apr 08.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40203516
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lauer+UM%22">Lauer UM</searchLink>; Department of Internal Medicine VIII, Medical Oncology & Pneumology, University Hospital Tübingen, Tübingen, Germany; German Cancer Research Center (DKFZ), Member of the German Cancer Consortium (DKTK), Tübingen, Germany. Electronic address: ulrich.lauer@uni-tuebingen.de.<br /><searchLink fieldCode="AU" term="%22Awada+A%22">Awada A</searchLink>; Oncology Medicine Department, Jules Bordet Institute, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Postel-Vinay+S%22">Postel-Vinay S</searchLink>; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; INSERM Unit U981, Gustave Roussy, Villejuif, France; University College of London Cancer Institute, London, UK.<br /><searchLink fieldCode="AU" term="%22Shapiro+GI%22">Shapiro GI</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Thieblemont+C%22">Thieblemont C</searchLink>; Université Paris Cité & Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Hémato-oncologie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Paik+PK%22">Paik PK</searchLink>; Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.<br /><searchLink fieldCode="AU" term="%22Shepard+DR%22">Shepard DR</searchLink>; Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, USA.<br /><searchLink fieldCode="AU" term="%22Docampo+LI%22">Docampo LI</searchLink>; Lung and Head and Neck Cancer Unit, Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Galot+R%22">Galot R</searchLink>; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Rottey+S%22">Rottey S</searchLink>; Drug Research Unit Ghent, Ghent University Hospital, Ghent, Belgium.<br /><searchLink fieldCode="AU" term="%22Sadrolhefazi+B%22">Sadrolhefazi B</searchLink>; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, USA.<br /><searchLink fieldCode="AU" term="%22Marzin+K%22">Marzin K</searchLink>; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.<br /><searchLink fieldCode="AU" term="%22Musa+H%22">Musa H</searchLink>; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.<br /><searchLink fieldCode="AU" term="%22Schöffski+P%22">Schöffski P</searchLink>; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101690685%22">ESMO open</searchLink> [ESMO Open] 2025 May; Vol. 10 (5), pp. 104499. <i>Date of Electronic Publication: </i>2025 Apr 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101690685 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-7029 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220597029%22">20597029 </searchLink><i>NLM ISO Abbreviation: </i>ESMO Open <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40203516
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.esmoop.2025.104499
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 104499
    Titles:
      – TitleFull: Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lauer UM
      – PersonEntity:
          Name:
            NameFull: Awada A
      – PersonEntity:
          Name:
            NameFull: Postel-Vinay S
      – PersonEntity:
          Name:
            NameFull: Shapiro GI
      – PersonEntity:
          Name:
            NameFull: Thieblemont C
      – PersonEntity:
          Name:
            NameFull: Piha-Paul SA
      – PersonEntity:
          Name:
            NameFull: Paik PK
      – PersonEntity:
          Name:
            NameFull: Shepard DR
      – PersonEntity:
          Name:
            NameFull: Docampo LI
      – PersonEntity:
          Name:
            NameFull: Galot R
      – PersonEntity:
          Name:
            NameFull: Rottey S
      – PersonEntity:
          Name:
            NameFull: Sadrolhefazi B
      – PersonEntity:
          Name:
            NameFull: Marzin K
      – PersonEntity:
          Name:
            NameFull: Musa H
      – PersonEntity:
          Name:
            NameFull: Schöffski P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2025 May
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2059-7029
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: ESMO open
              Type: main
ResultId 1